Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has patented glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, obesity, glucose intolerance, dyslipidemia, hyperinsulinemia and insulin resistance.